Factores pronósticos en el trasplante cardiopulmonar: experiencia a 30 años en un centro de referencia / Prognosis factors in heart–lung transplantation: Thirty years experience in a reference center

Introducción: El trasplante cardiopulmonar (TCP) ha presentado una disminución progresiva en el número de procedimientos. En nuestro país existe poca información al respecto, siendo el objetivo de este estudio analizar la experiencia de un hospital de referencia. Métodos: Estudio observacional unicéntrico de una cohorte histórica en el periodo entre 1990 y 2021. Las asociaciones entre categorías se evaluaron mediante la prueba de X2 o la f de Fisher. La supervivencia se analizó a través del método de Kaplan-Meier. Las diferencias se evaluaron con el estudio de log-rank y el análisis multivariante con el método de Cox. Resultados: Se observó una reducción del número de procedimientos realizados en el último decenio (2000-2009: 19 [44,2%]; 2010-2021: 15 [34,8%]). La mortalidad posoperatoria precoz fue de 23,3%, reduciéndose a 13,3% a partir del 2010. La intrahospitalaria fue de 41%, disminuyendo a 33% en 2010. Los factores asociados a la mortalidad fueron cirugía torácica previa, corticoterapia, circulación extracorpórea (CEC) mayor a 200 min, tiempo de isquemia mayor a 300 min y dehiscencia traqueal (p < 0,005). La supervivencia global a uno, cinco y 10 años fue de 58, 44,7 y 36,1%, respectivamente. Los factores asociados a menores tasas de supervivencia fueron cirugía torácica previa, donante masculino, CEC mayor 200 min, tiempo de isquemia mayor a 300 min, dehiscencia traqueal y diferencia de pesos (p < 0,005). Conclusiones: Existe una disminución en el número de procedimientos, siendo más evidente en la última década, pero evidenciando una mejora tanto de la mortalidad posoperatoria y supervivencia.(AU)

Introduction: Heart–lung transplantation has shown a progressive decrease in the number of procedures. There is a lack of information about this field in Spain. The main goal of this study is to analyze the experience of a national reference hospital. Methods: We performed a retrospective study of a historical cohort of heart–lung transplanted patients in a single center, during a 30 years period (from 1990 to 2021). The associations between variables were evaluated using the χ2 test or Fisher's exact test. Survival was analyzed using the Kaplan–Meier method. Differences were evaluated using the log-rank test and multivariate analysis with the Cox method. Results: A decrease in the number of procedures performed in the last decade was observed [2000–2009: 19 procedures (44.2%); 2010–2021: 15 procedures (34.8%)]. Early postoperative mortality was 23.3%, falling to 13.3% from 2010. In-hospital mortality was 41%, falling to 33% from 2010. Main factors related to higher mortality: previous thoracic surgery, corticosteroid therapy, extracorporeal circulation (ECLS) greater than 200 min, ischemia time greater than 300 min, and tracheal dehiscence (p < 0.005). Overall survival at one, five, and ten years was 58%, 44.7%, and 36.1%, respectively. Factors associated with lower survival rates: previous thoracic surgery, male donor, extracorporeal circulation greater than 200 min, ischemia time greater than 300 min, tracheal dehiscence and weight difference (p < 0.005). Conclusions: There has been a progressive decrease in the number of heart–lung transplantations, being more evident in the last decade, but showing an improvement in both mortality and survival.(AU)

Retrasplante pulmonar. Experiencia de un centro de referencia / Lung retransplant. Experience of a referral centre

ANTECEDENTES Y OBJETIVOS: El retrasplante pulmonar (RTP) es un tratamiento válido en pacientes con disfunción pulmonar, pero con una elevada morbimortalidad. Nuestro objetivo es analizar nuestra experiencia en RTP en supervivencia y función pulmonar. PACIENTES Y MÉTODOS: Estudio retrospectivo de pacientes con RTP (1990-2019). VARIABLES: receptores y procedimiento, mortalidad precoz, supervivencia y función pulmonar en pacientes CLAD. Variables cuantitativas (media±DE); cualitativas (%). Se utilizó el test t de Student o χ2. La supervivencia se estimó mediante Kaplan-Meier, comparándose con Log Rank. Se estableció como significativa p < 0,05. RESULTADOS: De 784 pacientes trasplantados, 25 pacientes (edad media 38,41 ± 16,3 años, 12 hombres y 13 mujeres) fueron RTP; CLAD (n = 19), infarto pulmonar (n = 2), complicaciones de vía aérea (n = 2), disfunción del injerto (n = 1), rechazo hiperagudo (n = 1). Tiempo medio hasta el retrasplante: 5,41 ± 3,87 años en CLAD y 21,2 ± 21,4 días en no CLAD. La mortalidad a 90 días fue del 52% y 36,8% en el segundo periodo (p = 0,007), siendo mayor en pacientes que precisaron ECMO preoperatorio (80 vs. 20%, p = 0,04). La supervivencia a 1 y 5 años fue del 53,9% y 37,7%, respectivamente (p = 0,016). La supervivencia del grupo CLAD fue mayor (p = 0,08). El ECMO pre RTP disminuyó la supervivencia (p = 0,032). FEV1 mejoró una media de 0,98 ± 0,13L (25,6 ± 18,8%) (p = 0,001). CONCLUSIONES: El RTP es un procedimiento de elevada mortalidad que obliga a una cuidadosa selección de los pacientes, con mejores resultados en aquellos con CLAD. La función pulmonar de los pacientes con CLAD mejoró significativamente

BACKGROUND: Lung retransplantation (LR) is a valid choice with a significant risk of perioperative morbidity and mortality in selected patients with graft dysfunction after lung transplantation. Our goal is to analyse our experience in LR in terms of survival and lung function. METHODS: Retrospective study of patients undergoing LR (1990-2019). VARIABLES: recipients and procedure, early mortality, survival and lung function in patients with CLAD. Quantitative variables (mean±SD); qualitative (%). Student's t test or χ2 was used. Survival was estimated using Kaplan-Meier, compared with Log Rank. A p < 0.05 was established as significant. RESULTS: Of 784 transplanted patients, 25 patients (mean age 38.41-16.3 years, 12 men and 13 women) were LR; (CLAD (n = 19), pulmonary infarction (n = 2), airway complications (n = 2), graft dysfunction (n = 1), hyperacute rejection (n = 1), mean time to retransplantation: 5.41 ± 3.87 years in CLAD and 21.2 ± 21.4 days in non-CLAD. The 90-day mortality was 52% and 36.8% in the second period (p = 0.007), being higher in patients who required preoperative ECMO (80 vs. 20%, p = 0.04). The 1- and 5-year survival was 53.9% and 37.7%, respectively (p = 0.016). Survival of the CLAD group was greater (p = 0.08). Pre LR ECMO decreased survival (p = 0.032). After LR, FEV1 improved an average of 0.98 ± 0.13L (25.6 ± 18.8%) (p = 0.001). CONCLUSIONS: LR is a high mortality procedure that requires careful selection of patients with better results in patients with CLAD. The lung function of patients with CLAD improved significantly

Lung retransplant. Experience of a referral centre. / Retrasplante pulmonar. Experiencia de un centro de referencia.

BACKGROUND: Lung retransplantation (LR) is a valid choice with a significant risk of perioperative morbidity and mortality in selected patients with graft dysfunction after lung transplantation. Our goal is to analyse our experience in LR in terms of survival and lung function. METHODS: Retrospective study of patients undergoing LR (1990-2019). VARIABLES: recipients and procedure, early mortality, survival and lung function in patients with CLAD. Quantitative variables (mean±SD); qualitative (%). Student's t test or χ2 was used. Survival was estimated using Kaplan-Meier, compared with Log Rank. A p < 0.05 was established as significant. RESULTS: Of 784 transplanted patients, 25 patients (mean age 38.41-16.3 years, 12 men and 13 women) were LR; (CLAD (n = 19), pulmonary infarction (n = 2), airway complications (n = 2), graft dysfunction (n = 1), hyperacute rejection (n = 1), mean time to retransplantation: 5.41 ± 3.87 years in CLAD and 21.2 ± 21.4 days in non-CLAD. The 90-day mortality was 52% and 36.8% in the second period (p = 0.007), being higher in patients who required preoperative ECMO (80 vs. 20%, p = 0.04). The 1- and 5-year survival was 53.9% and 37.7%, respectively (p = 0.016). Survival of the CLAD group was greater (p = 0.08). Pre LR ECMO decreased survival (p = 0.032). After LR, FEV1 improved an average of 0.98 ± 0.13L (25.6 ± 18.8%) (p = 0.001). CONCLUSIONS: LR is a high mortality procedure that requires careful selection of patients with better results in patients with CLAD. The lung function of patients with CLAD improved significantly.

Mortalidad perioperatoria del trasplante pulmonar en la enfermedad pulmonar obstructiva crónica / Perioperative mortality of lung transplantation in chronic obstructive pulmonary disease

Introducción: El trasplante pulmonar (TP) es una alternativa terapéutica en pacientes con EPOC en fase terminal. Nuestro objetivo es analizar la mortalidad perioperatoria (30 días) (MP) y los factores de riesgo que la condicionan en pacientes con EPOC sometidos a TP. Pacientes y método: Cohorte retrospectiva de 107 pacientes con EPOC trasplantados en el Hospital Universitario La Fe (1991-2008). Los datos demográficos, el grado de disnea, el diagnóstico, el índice BODE, el tipo de trasplante, la circulación extracorpórea, la edad del donante, la dependencia de glucocorticoides, la presencia de bronquiectasias, la reperfusión retrógrada, la transfusión de hemoderivados y la relación PaO2/FiO2 fueron analizadas. Las variables continuas se expresaron como media ± DE y las categóricas, con frecuencias absolutas y porcentajes. El análisis multivariante se realizó mediante el modelo de regresión de Cox. Resultados: Se trasplantaron 94 hombres y 13 mujeres con una edad media de 52,58 ± 8,05 años. El 75% de los pacientes tuvieron un BODE ≥ 7. Se realizaron 76 procedimientos bipulmonares. La MP fue del 14%. Las causas de muerte fueron las infecciones (53,3%) y las complicaciones quirúrgicas (33,3%). La presencia de bronquiectasias, el uso de glucocorticoides, la diferencia de talla entre receptor/donante y la presencia de émbolos grasos en la reperfusión retrógrada fueron factores de riesgo para la MP. La relación de PaO2/FiO2 a las 6 h fue un factor protector para la MP. Conclusiones: El TP es un procedimiento con una elevada tasa de MP. El uso previo de glucocorticoides, la presencia de bronquiectasias y de émbolos grasos en la reperfusión retrógrada, así como la PaO2/FiO2condicionaron la MP (AU)

Introduction: Lung transplantation (LT) has been considered an alternative therapeutic approach in terminal patients. However, this process in COPD is not controversy-free. This paper aimed to analyze 30-day mortality (PM) patterns and their risk factors in COPD patients undergoing LT. Patients and method: A retrospective cohort with 107 COPD patients, transplanted at the University La Fe Valencia, Spain, treated from January 1991 to December 2008. Demographics values, degree of dyspnoea, diagnosis, BODE index, single versus bilateral LT, cardio-pulmonary bypass, donor age, steroid dependence, presence of bronchiectasis, retrograde perfusion, transfusion of blood products, and PaO2/FiO2 were analyzed. Continuous variables were expressed as mean ± SD and categorical variables as absolute frequency and percentage. A Cox regression model was used for multivariate analysis. Results: Ninety-four men and 13 women of a mean age of 52.58 ± 8.05 years were transplanted. Of all patients, 75% obtained a BODE score above 7. There were 76 bilateral LT. PM was established at 14%. Main causes of death were infection (53.3%) and surgical complications (33.3%). Presence of bronchiectasis and chronic use of corticosteroids, donor/recipient difference in size and presence of fat in retrograde perfusion fluid were important risk factors for PM. Moreover, PaO2/FiO2 ratio at 6 h was a protective factor for the event, thus a higher ratio value, lowered the risk of PM. Conclusions: LT is a procedure with a high PM rate. Use of corticosteroids, the presence of bronchiectasis and fat emboli in the retrograde reperfusion, and PaO2/FiO2 significantly determine PM (AU)

[Perioperative mortality of lung transplantation in chronic obstructive pulmonary disease]. / Mortalidad perioperatoria del trasplante pulmonar en la enfermedad pulmonar obstructiva crónica.

INTRODUCTION: Lung transplantation (LT) has been considered an alternative therapeutic approach in terminal patients. However, this process in COPD is not controversy-free. This paper aimed to analyze 30-day mortality (PM) patterns and their risk factors in COPD patients undergoing LT. PATIENTS AND METHOD: A retrospective cohort with 107 COPD patients, transplanted at the University La Fe Valencia, Spain, treated from January 1991 to December 2008. Demographics values, degree of dyspnoea, diagnosis, BODE index, single versus bilateral LT, cardio-pulmonary bypass, donor age, steroid dependence, presence of bronchiectasis, retrograde perfusion, transfusion of blood products, and PaO2/FiO2 were analyzed. Continuous variables were expressed as mean±SD and categorical variables as absolute frequency and percentage. A Cox regression model was used for multivariate analysis. RESULTS: Ninety-four men and 13 women of a mean age of 52.58±8.05 years were transplanted. Of all patients, 75% obtained a BODE score above 7. There were 76 bilateral LT. PM was established at 14%. Main causes of death were infection (53.3%) and surgical complications (33.3%). Presence of bronchiectasis and chronic use of corticosteroids, donor/recipient difference in size and presence of fat in retrograde perfusion fluid were important risk factors for PM. Moreover, PaO2/FiO2 ratio at 6h was a protective factor for the event, thus a higher ratio value, lowered the risk of PM. CONCLUSIONS: LT is a procedure with a high PM rate. Use of corticosteroids, the presence of bronchiectasis and fat emboli in the retrograde reperfusion, and PaO2/FiO2 significantly determine PM.

Factores pronóstico en el carcinoma bronquial no microcítico menor de 3 centímetros (análisis actuarial, incidencia acumulativa y grupos de riesgo) / Prognostic factors in non-small cell lung cancer less than 3 centimeters: actuarial analysis, accumulative incidence and risk groups

Introducción: En la clasificación TNM, los factores determinantes del factor T en el carcinoma pulmonar no microcítico apenas han variado con el tiempo y todavía se basan únicamente en características anatómicas. Nuestro objetivo fue estudiar la influencia en la supervivencia de estos y otros factores de tipo morfopatológico. Métodos: Se incluyeron 263 pacientes sometidos a resección pulmonar por carcinoma pulmonar no microcítico en estadio I patológico y diámetro ≤ 3 cm. Se realizó un estudio de supervivencia y de estimación del riesgo competitivo observando variables clínicas, quirúrgicas y patológicas, siguiendo los métodos de análisis actuarial y de incidencia acumulativa, respectivamente. Posteriormente, se creó un modelo de riesgo de acuerdo con los resultados. Resultados: La supervivencia fue de 79,8 y 74,3% a los 5 y 10 años, respectivamente. Los factores con mejor pronóstico, estadísticamente significativo según el método actuarial fueron: presencia de síntomas, hábito tabáquico, FEV1 > 60%, número de ganglios resecados > 7, tipo histológico escamoso, ausencia de invasión vascular, ausencia de invasión pleural visceral y presencia de invasión bronquial lobar proximal. La edad < 50 años rozó la significación estadística. En el análisis multivariante entraron en regresión la invasión pleural visceral y la invasión vascular. El estudio de riesgo competitivo mostró una probabilidad de muerte por cáncer de 14,3 y 35,1% en 5 y 10 años, respectivamente. Las variables significativas en los análisis univariante y multivariante fueron similares excepto el FEV1 > 60%. Conclusiones: La presencia de invasión pleural visceral y la invasión vascular determina la supervivencia o el riesgo de muerte por carcinoma pulmonar no microcítico ≤ 3 cm y permiten elaborar un modelo predictivo de riesgo

Introduction: In TNM classification, factors determining the tumor (T) component in non-small cell lung cancer have scarcely changed over time and are still based solely on anatomical features. Our objective was to study the influence of these and other morphopathological factors on survival. Methods: A total of 263 patients undergoing lung resection due to stage I non-small cell lung cancer ≤ 3 cm in diameter were studied. A survival analysis and competing-risk estimate study was made on the basis of clinical, surgical and pathological variables using actuarial analysis and accumulative incidence methods, respectively. A risk model was then generated from the results Results: Survival at 5 and 10 years was 79.8 and 74.3%, respectively. The best prognostic factors were presence of symptoms, smoking habit and FEV1 > 60%, number of resected nodes > 7, squamous histology, absence of vascular invasion, absence of visceral pleural invasion and presence of invasion more proximal than the lobar bronchus. All these were statistically significant according to the actuarial method. The factor 'age < 50 years' was close to the margin of statistical significance. Pleural invasion and vascular invasion were entered in the multivariate analysis. The competing-risk analysis showed a probability of death due to cancer of 14.3 and 35.1% at 5 and 10 years, respectively. Significant variables in the univariate and multivariate analyses were similar, with the exception of FEV1 > 60%. Conclusions: Pleural invasion and vascular invasion determine survival or risk of death due to non-small cell lung cancer ≤ 3 cm and can be used for generating a predictive risk model

Mortalidad en carcinoma pulmonar no microcítico resecado, con tamaño máximo de 3 cm y sin afectación ganglionar: análisis de riesgos competitivos / Mortality in early-stage, surgically resected non-small cell lung cancer less than 3 cm of size: Competing risk analysis

Fundamentos y objetivo: Los estudios de supervivencia en el carcinoma pulmonar no microcítico (CPNM) se basan, habitualmente, en el método de Kaplan-Meier. Sin embargo, otros factores, no contemplados por este método, pueden modificar la observación del suceso de interés. Existen modelos de incidencia acumulativa (IA) que, teniendo en cuenta estos riesgos competitivos, permiten estimaciones más precisas de la supervivencia y valorar el riesgo de muerte por otras causas. Nuestro objetivo es evaluar dichos modelos en pacientes operados de CPNM en estadio precoz. Pacientes y método: Estudio de 263 pacientes resecados de un CPNM con un diámetro ≤ 3 cm y sin afectación ganglionar (N0). Se analizaron variables demográfico-clínicas, morfopatológicas, quirúrgicas, clasificación TNM y evolución a largo plazo. Para el análisis de la IA se consideró suceso competitivo la mortalidad por otra causa. Para el análisis univariante se utilizó el método de Gray, y para el multivariante, el de Fine y Gray. Resultados: La mortalidad por CPNM fue del 19,4% a los 5 años y del 14,3% por otra causa. Ambas curvas se cruzaron a los 6,3 años, siendo la probabilidad de muerte por otra causa mayor a partir de este punto. En el análisis multivariante, condicionaron la mortalidad por cáncer la invasión pleural visceral (IPV) (p = 0,001) y la vascular (p = 0,020), mientras que para la mortalidad por otra causa diferente del cáncer lo fueron la edad > 50 años (p = 0,034), el tabaquismo (p = 0,009) y el índice de Charlson ≥ 2 (p = 0,000). Conclusiones: Mediante el método de IA, la IPV y la invasión vascular condicionaron la muerte por cáncer en CPNM > 3 cm y se determinaron cuáles fueron las causas no tumorales de muerte a largo plazo (AU)

Background and objective: Survival studies of non-small cell lung cancer (NSCLC) are usually based on the Kaplan-Meier method. However, other factors not covered by this method may modify the observation of the event of interest. There are models of cumulative incidence (CI), that take into account these competing risks, enabling more accurate survival estimates and evaluation of the risk of death from other causes. We aimed to evaluate these models in resected early-stage NSCLC patients. Patients and method: This study included 263 patients with resected NSCLC whose diameter was ≤ 3 cm without node involvement (N0). Demographic, clinical, morphopathological and surgical variables, TNM classification and long-term evolution were analysed. To analyse CI, death by another cause was considered to be competitive event. For the univariate analysis, Gray's method was used, while Fine and Gray's method was employed for the multivariate analysis. Results: Mortality by NSCLC was 19.4% at 5 years and 14.3% by another cause. Both curves crossed at 6.3 years, and probability of death by another cause became greater from this point. In multivariate analysis, cancer mortality was conditioned by visceral pleural invasion (VPI) (P = .001) and vascular invasion (P = .020), with age > 50 years (P = .034), smoking (P = .009) and the Charlson index ≥ 2 (P = .000) being by no cancer. Conclusions: By the method of CI, VPI and vascular invasion conditioned cancer death in NSCLC > 3 cm, while non-tumor causes of long-term death were determined (AU)

Resultados funcionales del trasplante pulmonar en la enfermedad pulmonar obstructiva crónica / Functional Outcomes After Lung Transplant in Chronic Obstructive Pulmonary Disease

Introducción: El trasplante pulmonar (TP) es una opción terapéutica con resultados controvertidos en la enfermedad pulmonar obstructiva crónica (EPOC). Nuestro objetivo es analizar los resultados del trasplante en términos de función pulmonar, así como identificar los factores pronósticos. Método: Se realizó un análisis retrospectivo de 107 pacientes con EPOC trasplantados en el Hospital Universitario La Fe entre 1991 y 2008. Se analizaron variables preoperatorias, estudio funcional pre y post-TP, variables del procedimiento quirúrgico y del seguimiento a largo plazo, expresadas en media o porcentaje según el caso, comparándose los resultados espirométricos antes y después del TP. Para el análisis multivariante se utilizó regresión lineal o logística según la variable. Resultados: Fueron trasplantados 94 hombres (87,9%) y 13 mujeres (12,1%), con una edad media ± desviación estándar de 52,58 ± 8,05 años; el 71% de TP fueron bipulmonares. Los valores espirométricos mejoraron tras el TP: FVC: +1,22 l (+34,9%), FEV1: +1,66 l (+56,7%) y FEF25-75: +1,85 l (+50,8%); p = 0,001, manteniéndose esta mejoría funcional tras 5 años solo en el grupo con puntuación BODE > 7 (p = 0,001). La talla del receptor, el tipo de TP, la utilización de circulación extracorpórea durante el procedimiento quirúrgico, la presencia de síndrome de bronquiolitis obliterante junto con la edad y la causa de muerte del donante influyeron significativamente en la función pulmonar a largo plazo. Conclusiones: El TP mejora la función pulmonar de los pacientes con EPOC. Esta mejoría se mantiene a los 5 años solo en los pacientes con BODE mayor de 7. El trasplante bipulmonar proporciona mejores resultados funcionales que el unipulmonar

Introduction: Lung transplantation (LT) is a therapeutic option with controversial results in chronic obstructive pulmonary disease (COPD). We aimed to analyze the outcomes of transplantation in terms of lung function and to identify prognostic factors. Method: A retrospective analysis of 107 patients with COPD receiving lung transplants in the La Fe Hospital between 1991 and 2008 was performed. Preoperative variables, pulmonary function tests before and after LT, surgical procedure variables and long-term monitoring, expressed as mean or percentage, as applicable, were analyzed. Spirometric results before and after LT were analyzed. Linear or logistic regression were used for multivariate analysis depending on the variable. Results: Ninety-four men (87.9%) and 13 women (12.1%) were transplanted, with a mean age ± standard deviation of 52.58 ± 8.05 years; 71% of LTs were double-lung transplantations. Spirometric values improved after LT: FVC: +1.22 L (+34.9%), FEV1: +1.66 L (+56.7%) and FEF25-75: +1.85 L (+50.8%); P = .001. This functional improvement was maintained after 5 years only in the group with BODE score > 7 (P = .001). Recipient height, type of LT, use of extracorporeal circulation during the surgical procedure, presence of bronchiolitis obliterans syndrome and the age and cause of death of the donor significantly influenced lung function over time. Conclusions: LT improves lung function in COPD patients. This improvement was maintained at 5 years only in patients with BODE > 7. Double lung transplantation provides better functional results than single-lung transplantation

Prognostic Factors in Non-Small Cell Lung Cancer Less Than 3 Centimeters: Actuarial Analysis, Accumulative Incidence and Risk Groups.

INTRODUCTION: In TNM classification, factors determining the tumor (T) component in non-small cell lung cancer have scarcely changed over time and are still based solely on anatomical features. Our objective was to study the influence of these and other morphopathological factors on survival. METHODS: A total of 263 patients undergoing lung resection due to stage I non-small cell lung cancer ≤3cm in diameter were studied. A survival analysis and competing-risk estimate study was made on the basis of clinical, surgical and pathological variables using actuarial analysis and accumulative incidence methods, respectively. A risk model was then generated from the results. RESULTS: Survival at 5 and 10 years was 79.8 and 74.3%, respectively. The best prognostic factors were presence of symptoms, smoking habit and FEV1>60%, number of resected nodes>7, squamous histology, absence of vascular invasion, absence of visceral pleural invasion and presence of invasion more proximal than the lobar bronchus. All these were statistically significant according to the actuarial method. The factor "age<50 years" was close to the margin of statistical significance. Pleural invasion and vascular invasion were entered in the multivariate analysis. The competing-risk analysis showed a probability of death due to cancer of 14.3 and 35.1% at 5 and 10 years, respectively. Significant variables in the univariate and multivariate analyses were similar, with the exception of FEV1>60%. CONCLUSIONS: Pleural invasion and vascular invasion determine survival or risk of death due to non-small cell lung cancer ≤3cm and can be used for generating a predictive risk model.

Functional outcomes after lung transplant in chronic obstructive pulmonary disease.

INTRODUCTION: Lung transplantation (LT) is a therapeutic option with controversial results in chronic obstructive pulmonary disease (COPD). We aimed to analyze the outcomes of transplantation in terms of lung function and to identify prognostic factors. METHOD: A retrospective analysis of 107 patients with COPD receiving lung transplants in the La Fe Hospital between 1991 and 2008 was performed. Preoperative variables, pulmonary function tests before and after LT, surgical procedure variables and long-term monitoring, expressed as mean or percentage, as applicable, were analyzed. Spirometric results before and after LT were analyzed. Linear or logistic regression were used for multivariate analysis depending on the variable. RESULTS: Ninety-four men (87.9%) and 13 women (12.1%) were transplanted, with a mean age±standard deviation of 52.58±8.05 years; 71% of LTs were double-lung transplantations. Spirometric values improved after LT: FVC: +1.22L (+34.9%), FEV1: +1.66L (+56.7%) and FEF25-75: +1.85L (+50.8%); P=.001. This functional improvement was maintained after 5 years only in the group with BODE score >7 (P=.001). Recipient height, type of LT, use of extracorporeal circulation during the surgical procedure, presence of bronchiolitis obliterans syndrome and the age and cause of death of the donor significantly influenced lung function over time. CONCLUSIONS: LT improves lung function in COPD patients. This improvement was maintained at 5years only in patients with BODE>7. Double lung transplantation provides better functional results than single-lung transplantation.

[Mortality in early-stage, surgically resected non-small cell lung cancer less than 3 cm of size: Competing risk analysis]. / Mortalidad en carcinoma pulmonar no microcítico resecado, con tamaño máximo de 3 cm y sin afectación ganglionar: análisis de riesgos competitivos.

BACKGROUND AND OBJECTIVE: Survival studies of non-small cell lung cancer (NSCLC) are usually based on the Kaplan-Meier method. However, other factors not covered by this method may modify the observation of the event of interest. There are models of cumulative incidence (CI), that take into account these competing risks, enabling more accurate survival estimates and evaluation of the risk of death from other causes. We aimed to evaluate these models in resected early-stage NSCLC patients. PATIENTS AND METHOD: This study included 263 patients with resected NSCLC whose diameter was ≤ 3 cm without node involvement (N0). Demographic, clinical, morphopathological and surgical variables, TNM classification and long-term evolution were analysed. To analyse CI, death by another cause was considered to be competitive event. For the univariate analysis, Gray's method was used, while Fine and Gray's method was employed for the multivariate analysis. RESULTS: Mortality by NSCLC was 19.4% at 5 years and 14.3% by another cause. Both curves crossed at 6.3 years, and probability of death by another cause became greater from this point. In multivariate analysis, cancer mortality was conditioned by visceral pleural invasion (VPI) (P=.001) and vascular invasion (P=.020), with age>50 years (P=.034), smoking (P=.009) and the Charlson index ≥ 2 (P=.000) being by no cancer. CONCLUSIONS: By the method of CI, VPI and vascular invasion conditioned cancer death in NSCLC >3 cm, while non-tumor causes of long-term death were determined.

Bocio intratorácico. Revisión de la literatura médica / Intrathoracic goitre: A literature review

El bocio intratorácico se define como aquel bocio que se encuentra parcial o totalmente en el mediastino y que puede localizarse en el mediastino anterior o posterior; su incidencia está en relación con el bocio multinodular. El diagnóstico se realiza con cierta facilidad, en su mayoría con pruebas de imagen, y el tratamiento es variado, pero de elección se recomienda la cirugía. Con este artículo se pretende realizar una revisión de la literatura médica tanto del diagnóstico como del tratamiento de esta enfermedad (AU)

Intrathoracic goitre is defined as that goitre which is partially or totally found in the anterior or posterior mediastinum, and its incidence is associated with multinodular goitre. The diagnosis is relatively easy, mainly with imaging tests, and treatment varies, but of choice, surgical treatment is recommended. This article attempts to present a review of the literature on the diagnosis and management of this disease (AU)

[Intrathoracic goitre: a literature review]. / Bocio intratorácico. Revisión de la literatura médica.

Intrathoracic goitre is defined as that goitre which is partially or totally found in the anterior or posterior mediastinum, and its incidence is associated with multinodular goitre. The diagnosis is relatively easy, mainly with imaging tests, and treatment varies, but of choice, surgical treatment is recommended. This article attempts to present a review of the literature on the diagnosis and management of this disease.

Endotracheal metastases from colon adenocarcinoma.

Endotracheal metastases (ETM) from non-lung cancer are seldom seen. Their main clinical symptoms are cough, haemoptysis and dyspnoea, although occasionally an incidental finding is made during a bronchoscopy. Breast, colon and kidney adenocarcinoma might be associated with ETM, lung cancer being the most frequent cause. Its finding is associated with advanced disease but survival will depend on the primary origin, patient status and comorbidity. Therefore, treatment should be individual for each patient. In our centre we recommend pre-surgery bronchoscopy to exclude metastatic endotracheal lesions in patients with metastatic colon adenocarcinoma disease, as this might affect the final outcome and therefore management of the disease.

Lesión lítica esternal. Una presentación atípica de la tuberculosis / Sternal lithic lesion. An atypical presentation of tuberculosis

No disponible

[Lung transplantation: bronchogenic carcinoma in the native lung]. / Trasplante pulmonar. Carcinoma broncogénico en pulmón nativo.

In lung transplantation, the presence of bronchogenic carcinoma in the native organ is uncommon, but doubtless affects patient survival, independently of the transplantation process itself. We describe 2 cases in which a primary tumor was found in the explanted lung--1 case of adenocarcinoma in a patient with pulmonary emphysema and 1 case of bronchioloalveolar carcinoma in a patient with idiopathic pulmonary fibrosis. Both patients died due to the recurrence of the neoplastic disease. Distant metastasis was the initial manifestation of the recurrence.

Trasplante pulmonar. Carcinoma broncogénico en pulmón nativo / Lung transplantation: bronchogenic carcinoma in the native lung

En el trasplante pulmonar, la presencia de un carcinoma broncogénico en el órgano nativo es una situación muy poco frecuente, pero que, sin duda, condiciona la supervivencia de los pacientes, independientemente del propio proceso del trasplante en sí. Se describen 2 casos donde se hallaron sendos tumores primarios pulmonares en el órgano extraído, un adenocarcinoma en el contexto de un enfisema pulmonar, y un carcinoma bronquioloalveolar en un paciente con fibrosis pulmonar idiopática. Ambos pacientes fallecieron por la recidiva de la enfermedad neoplásica, cuya manifestación inicial fue la presencia de enfermedad metastásica a distancia

In lung transplantation, the presence of bronchogenic carcinoma in the native organ is uncommon, but doubtless affects patient survival, independently of the transplantation process itself. We describe 2 cases in which a primary tumor was found in the explanted lung--1 case of adenocarcinoma in a patient with pulmonary emphysema and 1 case of bronchioloalveolar carcinoma in a patient with idiopathic pulmonary fibrosis. Both patients died due to the recurrence of the neoplastic disease. Distant metastasis was the initial manifestation of the recurrence

Neumotórax contralateral espontáneo tras neumonectomía por carcinoma broncogénico / Spontaneous contralateral pneumothorax after pneumonectomy for bronchogenic carcinoma

No disponible